As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
The Secretary of Health (SOH) approves nine (9) Health Technologies with HTA Council Final Recommendations for inclusion in the Philippine National Formulary (PNF)
On 11 August 2025, the Secretary of Health (SOH) approved the inclusion of the following health technologies (HTs) in the Philippine National Formulary through the Department of Health (DOH) Department Circular 2025-0341. This approval follows the recommendations previously submitted by the HTA Council: For the full details on the HTA Council Final Recommendation such as continue reading : The Secretary of Health (SOH) approves nine (9) Health Technologies with HTA Council Final Recommendations for inclusion in the Philippine National Formulary (PNF)